Sandra Cuellar, PharmD, BCOP, FASHP | Authors

Expert Commentary on the Product Profile of Margetuximab for HER2-Positive Breast Cancer

September 21, 2021

In an interview with ONCOLOGY®, Sandra Cuellar, PharmD, BCOP, FASHP, offers a comprehensive review of real-world treatment considerations of margetuximab as therapy for adult patients with metastatic HER2-positive breast cancer who have received 2 or more prior anti-HER2 regimens with at least 1 being for metastatic disease.